drugset / Trial / NCT03955458

EXPAREL Facia Iliaca Compartment Block for Intertrochanteric Hip Fracture

NCT03955458 ↗

Phase 4 Withdrawn Pacira Pharmaceuticals, Inc
RandomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates the effect of EXPAREL on total opioid consumption through 72 hours following fascia iliaca compartment block (FICB) in subjects undergoing repair of intertrochanteric hip fracture.

Timeline

Start
2019-08-26
Primary completion
2020-05
Completion
2020-05

Outcome

Outcome not reported

Stopped (Enrollment): “Recruitment difficulties”

Drugs

EvaluationDrugModalityDoseRoute
Background Bupivacaine Other / unclassified — Other
Comparator Ropivacaine Other / unclassified — Other
Background Bupivacaine Other / unclassified — Other

Indications

No indication recorded.